Incyte Biosciences Denmark ApS: Financial statements 2025
CVR: 35818790
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Incyte Biosciences Denmark ApS (CVR 35818790) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 6,696,586 and a net result of DKK 361,151 compared with DKK 368,873 the year before. That is a decrease of 5% compared with the year before. Equity in the 2025 report amounted to DKK 2,328,496. The solvency ratio was 58.1%. The company had 4 employees in the financial year.
- Gross Profit
- DKK 6,696,586
- Profit/Loss
- DKK 361,151
- Equity
- DKK 2,328,496
- Total Assets
- DKK 4,009,953
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 6.7M | 361K | 2.3M | 4 |
| 2024 | - | 7M | 369K | 2M | 4 |
| 2023 | - | 6.3M | 375K | 1.6M | 4 |
| 2022 | - | 5.6M | 278K | 1.2M | 4 |
| 2021 | - | 5.3M | 269K | 946K | 4 |
Official annual report
How creditworthy is Incyte Biosciences Denmark ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Incyte Biosciences Denmark ApS has published its annual report for 2024. Gross profit came to DKK 7,046,348, and the net result was DKK 368,873.
As of February 27, 2025, Erik Garardus Johannes Bokmans has joined the board of directors of Incyte Biosciences Denmark ApS.
As of February 27, 2025, Erik Thomas Fromm has left the board of directors of Incyte Biosciences Denmark ApS.
As of February 27, 2025, Erik Garardus Johannes Bokmans is registered as director of Incyte Biosciences Denmark ApS.
As of February 27, 2025, Erik Thomas Fromm has stepped down as director of Incyte Biosciences Denmark ApS.
About Incyte Biosciences Denmark ApS
Incyte Biosciences Denmark ApS is a Danish company of the type Anpartsselskab based in Frederiksberg C, founded in 2014. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named ARIAD PHARMACEUTICALS (DENMARK) ApS. The management consists of Ebba Cecilia Bröms. The board consists of Lee Jason Heeson (chair) and Ebba Cecilia Bröms. The company is owned by Incyte Biosciences International Sàrl. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK 6,696,586 and a net result of DKK 361,151 compared with DKK 368,873 the year before. Equity in the 2025 report amounted to DKK 2,328,496.
